Global Alzheimer’s Therapeutics Market Growth 2023-2029

Global Alzheimer’s Therapeutics Market Growth 2023-2029

Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia.

LPI (LP Information)' newest research report, the “Alzheimer’s Therapeutics Industry Forecast” looks at past sales and reviews total world Alzheimer’s Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Alzheimer’s Therapeutics sales for 2023 through 2029. With Alzheimer’s Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Alzheimer’s Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Alzheimer’s Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Alzheimer’s Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Alzheimer’s Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Alzheimer’s Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Alzheimer’s Therapeutics.

The global Alzheimer’s Therapeutics market size is projected to grow from US$ 4521.5 million in 2022 to US$ 6745.8 million in 2029; it is expected to grow at a CAGR of 6745.8 from 2023 to 2029.

Europe is estimated to grow at a rapid pace owing to the high prevalence of AD coupled with ever improving diagnostic capabilities. Asia Pacific is expected to witness the fastest growth over the forecast period owing to the rising disposable income level.

This report presents a comprehensive overview, market shares, and growth opportunities of Alzheimer’s Therapeutics market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Donepezil
Memantine
Rivastigmine

Segmentation by application
Early to Moderate Stages
Moderate to Severe Stages

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Merck &
Novartis AG
Eisai
H. Lundbeck A/S
AC Immune
TauRx Pharmaceuticals
Actavis plc.
Forest Laboratories
Teva Pharmaceuticals Industries
Janssen Pharmaceutical
GE healthcare
Eli Lilly And Company
DiaGenic ASA
VTV Therapeutics
Hoffman-La Roche
AstraZeneca
Daiichi Sankyo Company

Key Questions Addressed in this Report

What is the 10-year outlook for the global Alzheimer’s Therapeutics market?

What factors are driving Alzheimer’s Therapeutics market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Alzheimer’s Therapeutics market opportunities vary by end market size?

How does Alzheimer’s Therapeutics break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.